Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.

[1]  J. Mestan,et al.  Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia. , 2005, Biochimica et biophysica acta.

[2]  A. Tefferi.  Pathogenesis of myelofibrosis with myeloid metaplasia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  K. Bhalla,et al.  AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has Significant Activity in Imatinib-Resistant Chronic Myeloid Leukemia (CML) or Philadelphia-Chromosome Positive Acute Lymphoid Leukemia (Ph + ALL). , 2005 .

[4]  Sandra A. Moore,et al.  The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo. , 2005, Blood.

[5]  H. Kantarjian,et al.  Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia. , 2005, Current molecular medicine.

[6]  Hannah Al.  Kinases as drug discovery targets in hematologic malignancies. , 2005 .

[7]  Z. Estrov,et al.  AMN107, a novel aminopyrimidine inhibitor of p190 Bcr‐Abl activation and of in vitro proliferation of Philadelphia‐positive acute lymphoblastic leukemia cells , 2005, Cancer.

[8]  S. Galimberti,et al.  Imatinib therapy in Hypereosinophilic Syndrome: a case of molecular remission. , 2005, Leukemia research.

[9]  J. Mestan,et al.  AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia , 2005, Clinical Cancer Research.

[10]  J. Mestan,et al.  In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. , 2005, Cancer research.

[11]  Donna Neuberg,et al.  Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. , 2005, Cancer cell.

[12]  Randy Allred,et al.  A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. , 2005, Blood.

[13]  H. Kantarjian,et al.  Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia , 2004, Cancer.

[14]  P. Marynen,et al.  The EOL-1 cell line as an in vitro model for the study of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. , 2004, Blood.

[15]  M. L. Bousse-Kerdilès,et al.  Myelofibrosis: pathogenesis of myelofibrosis with myeloid metaplasia , 2000, Springer Seminars in Immunopathology.

[16]  H. Kantarjian,et al.  SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. , 2003, Blood.

[17]  H. Kantarjian,et al.  Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. , 2003, Blood.

[18]  D. Fabbro,et al.  PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRα-induced myeloproliferative disease. , 2003, Cancer cell.

[19]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[20]  H. Kantarjian,et al.  Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. , 2002, Leukemia research.

[21]  I. Lampert,et al.  ST1571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. , 2002, American journal of clinical pathology.

[22]  B. Druker,et al.  STI571: targeting BCR-ABL as therapy for CML. , 2001, The oncologist.

[23]  L. Khachigian,et al.  Identification of PDGF Receptors on Human Megakaryocytes and Megakaryocytic Cell Lines , 1997, Thrombosis and Haemostasis.

[24]  Y. Satow,et al.  Platelet‐derived growth factor expression in accelerated and blastic phase of chronic myelogenous leukaemia with myelofibrosis , 1994, British journal of haematology.